Most of the Effect of Paroxetine for Treating Hot Flashes May Be Placebo Effect
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, Sept. 5, 2023 -- Most of the efficacy of paroxetine to treat hot flashes may be a placebo effect, according to a review published online Aug. 4 in Frontiers in Psychiatry.
Joshua R. Rhodes, Ph.D., from Abilene Christian University in Texas, and colleagues conducted a systematic literature review to identify randomized clinical trials examining the efficacy of paroxetine to treat hot flashes.
Six randomized clinical trials (1,486 women) were included in a meta-analysis.
The researchers found that 79 percent of the mean treatment response for hot flash frequency was accounted for by a placebo response, resulting in a mean true drug effect of 21 percent at most across the six trials. For hot flash severity, 68 percent of the mean treatment response was accounted for by a placebo response, resulting in a maximum true drug effect of 32 percent.
“The findings provide evidence to reevaluate the use of paroxetine to treat postmenopausal hot flashes and emphasize the importance of considering effective, alternative treatments for vasomotor symptoms,” the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Menopausal Hormone Therapy Use Beyond 65 Years Beneficial
TUESDAY, April 16, 2024 -- Use of menopausal hormone therapy beyond age 65 years is associated with risk reductions in mortality as well as specific cancers and cardiovascular...
Perceived Social Isolation Tied to Altered Brain Processing of Food Cues
TUESDAY, April 9, 2024 -- Social isolation is associated with altered brain processing of food cues in premenopausal women, according to a study published online April 4...
Endocrine, Vascular Processes Contribute to Cognitive Decline in Women
WEDNESDAY, April 3, 2024 -- For female adults, endocrine and vascular processes synergistically contribute to an increased risk for cognitive decline, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.